Exclusive: Teva faces EU fine for disparaging rival multiple sclerosis medicine, sources say
Teva , the world's largest generic drugmaker, will be hit with an EU antitrust fine in the coming weeks for disparaging a rival product to its blockbuster multiple sclerosis medicine Copaxone, people with direct knowledge of the matter said on Tuesday.
Cheap Teva Stock Should Reward Patient Investors
Teva is poised to benefit from rising demand for generic drugs due to a favorable macro and political environment. The company's valuation is attractive despite its high debt load, which it is likely to manage effectively. Teva's generic drug revenue surged 16% in Q2, and the unit's continued growth is expected to significantly boost the firm's overall revenue.
Teva Pharmaceutical Industries Limited (TEVA) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)
Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Morgan Stanley 22nd Annual Global Healthcare Conference Call September 4, 2024 11:30 AM ET Company Participants Richard Francis - Chief Executive Officer Conference Call Participants Thibault Boutherin - Morgan Stanley Thibault Boutherin So, good morning, everyone, and thank you for joining this session of the Morgan Stanley Global Healthcare Conference. I am Thibault Boutherin.
2 Reasonably Priced Stocks to Keep an Eye On
Teva Pharmaceutical Industries Ltd (NYSE:TEVA) and Hewlett Packard Enterprise Co (NYSE:HPE) are this week's picks for Schaeffer's Cheap Seats : Stocks Under $20 segment.
Teva's Transformation: From Generics Leader To Branded Drug Innovator
Step by step, Teva's management is making progress in transforming it from a generic drugmaker into one that will play a key role in the fight against immune-related disorders. Its revenue was about $4.16 billion in the second quarter of 2024, up 7.2% year-on-year. So, in addition to the growth in sales of its generic products, there is also increased demand for innovative medications, including Austedo and Uzedy.
TEVA Q2 Earnings Beat, Generic Business Drives Sales, Stock Up
TEVA reports better-than-expected second-quarter results, beating both earnings and sales estimates. Management raises the 2024 financial outlook.
Teva Pharmaceutical Industries Limited (TEVA) Q2 2024 Earnings Call Transcript
Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Q2 2024 Earnings Conference Call July 31, 2024 8:00 AM ET Company Participants Richard Francis - President & CEO Eli Kalif - CFO Eric Hughes - Head, R&D & Chief Medical Officer Ran Meir - SVP, head of IR Conference Call Participants Ash Verma - UBS Balaji Prasad - Barclays David Amsellem - Piper Sandler Jason Gerberry - Bank of America Omri Efroni - Oppenheimer Umer Raffat - Evercore Glen Santangelo - Jefferies Chris Schott - J.P. Morgan Yifeng Liu - HSBC Operator Hello, and welcome to the Teva Pharmaceuticals Industries Limited Q2 2024 Earnings Call.
Teva Pharmaceutical Industries (TEVA) Reports Q2 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Teva Pharmaceutical Industries (TEVA) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Is Teva Pharmaceutical Industries (TEVA) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Unveiling Teva Pharmaceutical Industries (TEVA) Q2 Outlook: Wall Street Estimates for Key Metrics
Evaluate the expected performance of Teva Pharmaceutical Industries (TEVA) for the quarter ended June 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Teva's Q2 Outlook: Key Developments In Biosimilars And Pipeline Drugs
Teva Pharmaceutical's stock is up 69% since December, driven by legal resolution, blockbuster drugs, debt reduction, and new product launches. Recent developments include the launch of biosimilars and generics, positive data on Uzedy and Ajovy, and an accelerated timeline for TEV-48574. Financially, Teva's current ratio is under 1, with upcoming debt maturities posing a challenge. Recommendation remains "Hold" pending Q2 earnings.
TEVA's Ajovy Meets Goal in Migraine Prevention Study for Kids
TEVA achieves the primary efficacy endpoint with statistical significance in the phase III study of its marketed drug, Ajovy, for the prevention of episodic migraine in pediatric patients.
